% | $
Quotes you view appear here for quick access.

Shire plc Message Board

  • blackoutbuzz blackoutbuzz Mar 29, 2012 12:31 PM Flag

    New Replagal data

    I assume this is to demonstrate that there is no long term concern switching from Fabrazyme to Replagal.

    NYON, Switzerland, March 29, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, presented data that show favorable treatment effect and tolerability of REPLAGAL® (agalsidase alfa) in Fabry patients who switched from Fabrazyme® (agalsidase beta) or were naive to enzyme replacement therapy (ERT) after one year of treatment with REPLAGAL at the America College of Medical Genetics (ACMG) annual meeting in Charlotte, NC.